Latest posts tagged with #IBDsky on Bluesky
In a large real-world study, more than 60% of patients with #CrohnsDisease treated with #risankizumab achieved steroid-free clinical remission by week 12, and through 1 year of treatment.
#Gastroenterology #GISky #inflammatoryBowelDisease #IBDSky
Colonic delivery of #FecalMicrobiotaTransplantation was a more effective route than nasogastric administration for patients with #UlcerativeColitis.
#Gastroenterology #InflammatoryBowelDisease #IBDSky #GISky #FMT
Taryn Lores, PhD, of the Icahn School of Medicine at Mount Sinai, discusses integrating #BehavioralIntervention therapy into treatment for patients with #CrohnsDisease.
#IBDSky #GISky
Tran concludes that additional molecular information provided by the molecular medicine board significantly improved therapy outcomes
#ECCO2026 #ECCO26 #GastroSky #IBDSky
Florian Tran presents results from GUIDE-IBD, a trial using an RNA-based biomarker to inform therapy guidance for patients with IBD initiating infliximab
#ECCO2026 #ECCO26 #GastroSky #IBDSky
Just presented at #ECCO2026 - 10-year data from the LIR!C trial comparing ileocaecal resection vs infliximab for ileal Crohn’s disease
Now published in @lancetgastrohep.bsky.social
www.thelancet.com/journals/lan...
#ECCO26 #GastroSky #MedSky #IBDSky
#GLP1 receptor agonists may be a safe and beneficial option for managing #obesity and metabolic comorbidities for adults with #InflammatoryBowelDisease.
#GISky #IBDSky
Real-world data presented at #CCCongress26 suggest IV and SC #vedolizumab have similar overall safety and efficacy in IBD, but IV use was linked to higher hospitalization and steroid use (#UlcerativeColitis) and higher shock rates (#CrohnsDisease). #IBDSky #GISky
Phase 1b data suggest early efficacy signals for APL-1401, a first-in-class DBH inhibitor, in moderate-to-severe #UlcerativeColitis. Results presented at the #CCCongress26 support further dose evaluation. #GISky #IBDSky
Early CATHARSIS trial data presented at #CCCongress26 suggest combining biologics with structured #BrainGut behavioral therapy may improve well-being in moderate-severe #CrohnsDisease. High feasibility, satisfaction, and retention reported. #IBDSky #GISky
Phase 1 data presented at #CCCongress26 highlight ATH-063, a first-in-class oral G9a inhibitor. In healthy volunteers, it showed favorable PK, no safety signals, and strong FoxP3+ Treg activation—supporting further study in biologics-resistant IBD.
#IBDSky #GISky
Real-world data presented at #CCCongress26 suggest #GLP1 RAs may benefit #CrohnsDisease patients with overweight/obesity. #GLP1RA use was linked to lower steroid dependence, fewer hospitalizations, and improved durability of advanced IBD therapy. #IBDSky #GISky
Real-world data presented at #CCCongress26 suggest GLP-1 receptor agonists may improve #InflammatoryBowelDisease outcomes. In IBD, #GLP1 RA use was linked to lower steroid use, hospitalizations, surgery, and mortality, supporting further study. #GISky #IBDSky
Phase 1 results highlight SOR102, an oral bispecific TNF/IL-23p19 inhibitor, as a potential new therapy for #UlcerativeColitis. The first-in-human trial showed favorable safety and higher clinical response and remission rates vs placebo. #GISky #IBDSky
IL-23 is a key driver of chronic inflammation across the gut-skin-joint axis, transforming #InflammatoryBowelDisease care. IL-23 targeted therapy show durable efficacy, mucosal healing, and favorable safety, supporting earlier use in IBD treatment. #IBDSky #GISky
Nearly 20% of patients hospitalized with #UlcerativeColitis required #colectomy within 1 year despite #infliximab, underscoring the importance of early risk stratification and timely escalation of care in high-risk ASUC.
#IBDSky #GISky
New research - Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
New Comment - Menopause and inflammatory bowel disease: more questions than answers
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
New research - Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
www.thelancet.com/journals/lan...
#GastroSkt #MedSky #IBDSky
New review - Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
Ten-year #EpiIBD data show that earlier, more frequent use of biologics and small molecules did not improve long-term outcomes in #CrohnsDisease, with similar rates of surgery and progression across Europe. #GISky #IBDSky
Read further:
A meta-analysis suggests #MycophenolateMofetil may be a steroid-sparing option for adults with treatment-resistant #IBD, with ~60% achieving remission early and sustained benefit at 6 months in many patients.
#GISky #IBDSky
Read more at the link:
Etrasimod significantly improved both induction & maintenance remission in adults with #UlcerativeColitis. These findings add to growing evidence for S1P receptor modulation and highlight regional differences in UC treatment. #GISky #IBDSky
Read more at the link!
Data from the SHINE-1 trial highlight encouraging efficacy of #mirikizumab in children with #UlcerativeColitis and support its use as a potential emerging option for younger patients. #GISky #IBDSky
The next installment of #GTSRC will be in Snowbird! Come join us and bring your trainees for my favorite #GIresearch meeting 😍 #IBDsky #GIsky #Gastrosky
Our January 2026 issue is out now: www.thelancet.com/gastrohep
Content includes #MASH, #IBD, #PBC, #PSC, #ageing, #diet + more!
#GastroSky #MedSky #IBDSky
New Comment - Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
New research - Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
www.thelancet.com/journals/lan...
#GastroSky #MedSky #IBDSky
New research @eClinicalMed - A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
www.thelancet.com/journals/ecl...
#GastroSky #MedSky #IBDSky
